Literature DB >> 19300241

Anaphylaxis in patients with congenital bleeding disorders and inhibitors.

Massimo Franchini1, Giuseppe Lippi, Martina Montagnana, Giovanni Targher, Marco Zaffanello, Gian Luca Salvagno, Gianna Franca Rivolta, Caterina Di Perna, Annarita Tagliaferri.   

Abstract

Anaphylactic reactions are rare emergencies observed in patients with inherited bleeding disorders. When these adverse events occur in patients with inhibitors, they further complicate the management of an already challenging clinical situation. Anaphylactoid inhibitors have been reported in patients with inhibitors associated with hemophilia A, hemophilia B, and type 3 von Willebrand disease. In this review, we summarize the current literature data on the occurrence of anaphylactoid reactions in patients with inherited bleeding disorders and alloantibodies. In particular, we focus on the pathophysiology of the inhibitor development and its management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300241     DOI: 10.1097/MBC.0b013e328329f265

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

1.  Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Erin L Kuether; Guowei Zhang; Qizhen Shi
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

2.  Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.

Authors:  Dheeraj Verma; Babak Moghimi; Paul A LoDuca; Harminder D Singh; Brad E Hoffman; Roland W Herzog; Henry Daniell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.

Authors:  H A Daniel Lagassé; Hartmut Hengel; Basil Golding; Zuben E Sauna
Journal:  AAPS J       Date:  2019-05-06       Impact factor: 4.009

4.  Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report.

Authors:  Margherita Mauro; Elisa Bonetti; Rita Balter; Giovanni Poli; Simone Cesaro
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

Review 5.  Alloantibodies in von Willebrand disease.

Authors:  Paula D James; David Lillicrap; Pier M Mannucci
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

6.  Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity.

Authors:  Jocelyn A Schroeder; Juan Chen; Yingyu Chen; Yuanhua Cai; Hongyin Yu; Jeremy G Mattson; Paul E Monahan; Qizhen Shi
Journal:  Blood Adv       Date:  2021-03-09

7.  Treatment of hemophilia B: focus on recombinant factor IX.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Cinzia Sissa; Carlo Bonfanti
Journal:  Biologics       Date:  2013-02-12

Review 8.  Platelet-Targeted Gene Therapy for Hemophilia.

Authors:  Qizhen Shi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-07       Impact factor: 6.698

Review 9.  How I manage severe von Willebrand disease.

Authors:  Frank W G Leebeek; Ferdows Atiq
Journal:  Br J Haematol       Date:  2019-09-09       Impact factor: 6.998

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.